Strategic Solutions for Prescription Drug Management in Canada Virtual Conference—Session Schedule, Speakers and Handouts

Session handouts will be available to registered attendees in the virtual environment when it opens on March 20, 2020. 

Please contact virtualconferences@ifebp.org if you have questions or need assistance.

In order to download session handouts you must be logged in and registered for the program.

Session handouts will be available to registered attendees Friday, March 20, 2020 through Saturday, March 20, 2021.

Filter by Track:  

Tuesday, March 31

7:00 AM – 5:00 PM

VC05  Test Your System

Access this session before attending the virtual conference to familiarize yourself with all of the features in the environment. (#3—Training and Education)

10:30 AM – 11:30 AM

VC01  The State of Pharmaceutical Policy in Canada

Chris Bonnett, M.HSc., Ph.D. (Cand.) Speaker
Principal Consultant
H3 Consulting
Guelph, ON

As federal and provincial policies evolve over the next few years, how will they affect private drug plans? Tune in to this session learn about:

  • Progress toward a national pharmacare program
  • Amendments and guidelines to PMPRB regulations
  • Canadian Drug Agency action, including the creation of a national formulary and increasing access to rare disease drugs
  • A “watch list” of other unresolved issues.
(#32—Health & Wellness)

11:45 AM – 12:45 PM

VC02  Trends in Specialty, Biologic and Biosimilar Drugs

Suzanne M. Lepage Speaker
Private Health Plan Strategist
Suzanne Lepage Consulting
Kitchener, ON

Join this session to learn about the state of the private payer market regarding pricing and access to specialty, biologic and biosimilar drugs. Discover:

  • How and why these drugs are impacting the private drug plans
  • How certain payer programs, such as managing formularies, delayed listings and preferred payer networks, may help to manage costs
  • Potential impact of different biosimilar policies.
(#32—Health & Wellness)

1:00 PM – 2:00 PM

VC03  Implementing Pharmacogenomics in Benefits Plans: A Real-Life Case Study

Moira Reiley, BSc. Biol., BSc. Pharm., PhC, BCGP Speaker
Consultant Pharmacist
Managed Health Care Svcs Inc
Dartmouth, NS

So what can pharmacogenomics really tell us and is that information worth it? Watch this session to learn about:

  • What pharmacogenomics testing is and what it isn’t
  • How testing is conducted
  • Who should be tested
  • The key benefits of testing
  • The different options and levels of application, including a case study of how the Halifax Professional Fire Fighters Benefits Trust implemented pharmacogenomics testing for its plan members.
(#32—Health & Wellness)

2:15 PM – 3:15 PM

VC04  Analyzing Medication Adherence in Canada

Karen Kesteris Speaker
Chief Product Officer
Express Scripts Canada
Mississauga, ON

Research indicates that nonadherence to prescribed medications can cause direct and indirect problems for the participant and the plan sponsor. Participants may experience treatment failures and hospitalizations, while plan sponsors deal with increases to prescription drug spend and other employee issues. Join this session to learn:

  • Some of the reasons that participants don’t take medications as prescribed
  • What data plan sponsors can access
  • How plan sponsors can integrate multiple data points (e.g., age, gender, plan design, drug therapeutic class, etc.) to make predictions about adherence.
(#32—Health & Wellness)